Share

January 15, 2019; 92 (3) Editorial

Forecasting outcomes in anti-NMDAR encephalitis

Clearer prognostic markers needed

Stephan Rüegg, E. Ann Yeh, Jerome Honnorat
First published December 21, 2018, DOI: https://doi.org/10.1212/WNL.0000000000006766
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
267

Share

Article Information

vol. 92 no. 3 119-120
DOI: 
https://doi.org/10.1212/WNL.0000000000006766
PubMed: 
30578369
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published December 21, 2018.

Article Versions

Copyright & Usage: 
© 2018 American Academy of Neurology

Author Disclosures

    1. Stephan Rüegg, MD,
    2. E. Ann Yeh, MD and
    3. Jerome Honnorat, MD, PhD
  1. Stephan Rüegg, MD,
    2. Scientific Advisory Boards:

    1. Serving on the advisory boards of: UCB (since 2004); Eisai (since 2005); GSK (since 2011); Desitin (since 2012)

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Novartis, speaker honorarium; talk at a Satelite Symposium during the trinational Epielpsy Meeting of the German-spekaing chapters of the ILAE 2017 (Vienna, Austria)

    Editorial Boards:

    1. Editorial Board:-EPILEPTOLOGIE (Journal of the Swiss League againstEpilepsy)-Swiss EEG Bulletin- Guest co-Editor Epilepsia Supplementum 2017 on the 2nd Meeting on Inflammation, Immunity and Epilepsy Held 2016 in Milan, Italy

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Swiss National Science Foundation; SPUM-Grant#33CM30-124115/1 4.2009-3.2012; Co-ISwiss National Science Foundation; SPUM-Grant #33CM30-140338/1 4.2012-3.2015; Co-ISwiss National Science Foundation; Co-PI#320030_169379/1 2017-2020

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. written expertise for county high court 2018

  2. E. Ann Yeh, MD and
    3. Scientific Advisory Boards:

    1. I perform MS relapse adjudication for ACI services on a fee-for-service basis. Juno therapeutics scientific advisory board 2017

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Neurology, editorial advisory board, 2013-present. MSJ editorial board 2016-present BMC Neurology editorial board 2016-present

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. 1) CIHR, Co-I. PI: Pohl 2) PCORI, Co-I, CE-1304-7079 3) CMSMS (CIHI/PHAC), MS Monitoring system pilot funding

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. 1) National MS Society HC 0148 2) National MS Society PP2256 3) MS Society (Canada) 4) Dairy Farmers of Ontario 5) SickKids Innovation Fund 6) MS Research Foundation (Canada) 7) Rare Diseases Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Jerome Honnorat, MD, PhD
    4. Scientific Advisory Boards:

    1. Scientific advisory board for Bristol Meyers Squibb

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. receives royalties from licensing fees to Athena Diagnostics, Euroimmun, and ravo Diagnostika for a patent for the use of CV2/CRMP5 as diagnostic tests.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Research support from CSL Behring France

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (S.R.), University Hospital Basel, Switzerland; Hospital for Sick Children (E.A.Y.), Division of Neurology, SickKids Research Institute, Neurosciences and Mental Health, University of Toronto, Canada; and French Reference Center on Paraneoplastic Neurological Syndrome (J.H.), Hospices Civils de Lyon, Institut NeuroMyoGene INSERM U1217/CNRS UMR 5310, Université de Lyon–Université Claude Bernard Lyon 1, France.
  1. Correspondence
    Dr. Rüegg Stephan.Rueegg{at}usb.ch
View Full Text

Article usage

Article usage: December 2018 to April 2022

AbstractFullPdfSource
Dec 2018262023Highwire
Jan 20193866660Highwire
Feb 20191321318Highwire
Mar 20191141327Highwire
Apr 201978715Highwire
May 201977611Highwire
Jun 20195236Highwire
Jul 201973314Highwire
Aug 20193817Highwire
Sep 20193267Highwire
Oct 20195067Highwire
Nov 20195306Highwire
Dec 20192823Highwire
Jan 20202216Highwire
Feb 20203256Highwire
Mar 20202405Highwire
Apr 20203226Highwire
May 20202631Highwire
Jun 20202046Highwire
Jul 20203112Highwire
Aug 20204155Highwire
Sep 20202522Highwire
Oct 20203201Highwire
Nov 20203720Highwire
Dec 20204102Highwire
Jan 20211701Highwire
Feb 20214311Highwire
Mar 20213210Highwire
Apr 20212711Highwire
May 20211612Highwire
Jun 20212111Highwire
Jul 20213023Highwire
Aug 20211802Highwire
Sep 20211004Highwire
Oct 20212411Highwire
Nov 20211900Highwire
Dec 20211933Highwire
Jan 20222120Highwire
Feb 20222312Highwire
Mar 20221700Highwire
Apr 20223000Highwire

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me